Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 3/20 | 0.60 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.60 |
| ▸ | PAK4 | O96013 | 2/20 | 0.60 |
| ▸ | PAK3 | O75914 | 2/20 | 0.60 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.60 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.60 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.60 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | WEE1 | P30291 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192788 | 0.90 | PAK4 (0.65) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL10192787 | 0.89 | PAK3 (0.75) | PAK1PKN1PAK4PAK3PAK2 | |
| Hydrochloric Acid SCHEMBL660053 | 0.88 | PAK3 (0.74) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL660399 | 0.88 | PAK3 (0.56) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15035152 | 0.82 | PAK1 (0.70) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15035162 | 0.82 | PAK1 (0.70) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15035165 | 0.80 | PAK1 (0.67) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15035147 | 0.80 | PAK1 (0.82) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL5762208 | 0.79 | FGFR1 (0.75) | RIPK2ACVR1NOD2EGFRFGFR1 | |
| SCHEMBL10192790 | 0.78 | WEE1 (0.77) | PAK1PKN1PAK4PAK3PAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519241-A2 | METHODS FOR TREATING AUTISM | Afraxis, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2504011-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | Afraxis, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011090666-A2 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |